Supraventricular tachyarrhythmias after hematopoietic stem cell transplantation: incidence, risk factors and outcomes BONE MARROW TRANSPLANTATION Hidalgo, J. D., Krone, R., Rich, M. W., Blum, K., Adkins, D., Fan, M. Y., Brown, R., Devine, S., Graubert, T., Blum, W., Tomasson, M., GOODNOUGH, L. T., Vij, R., DiPersio, J., Khoury, H. 2004; 34 (7): 615-619


Recent studies suggest that cancer patients may be at increased risk for supraventricular tachyarrhythmias (SVTA). We have observed clinically significant SVTA in patients undergoing hematopoietic stem cell transplantation occurring at a median of 6 days post transplant, manifesting as atrial fibrillation/flutter or regular narrow-complex tachycardia and persisting for a median of 3 days (range, 0-8). All patients received aggressive medical therapy and/or electrical cardioversion to restore sinus rhythm and to re-establish hemodynamic stability. Non-Hodgkin's lymphoma (NHL) was the most common diagnosis (53%), and a case control analysis in those patients demonstrated that SVTA occurred in 12% of patients and was associated with older age and pre-existing cardiac conditions. In conclusion, patients undergoing HSCT are at moderate risk for developing SVTA, particularly older patients with a diagnosis of NHL. These arrhythmias are clinically significant, and are a marker for increased mortality and prolonged hospital stay. Additional studies are needed to identify high-risk patients who may benefit from prophylactic anti-arrhythmic therapy.

View details for DOI 10.1038/sj.bmt.1704623

View details for Web of Science ID 000223884900009

View details for PubMedID 15258562